Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

BACKGROUND: The efficacy and safety of lenalidomide plus low-dose dexamethasone (Rd) in Chinese patients with relapsed/refractory multiple myeloma (RRMM) was demonstrated in a phase 2, multicenter trial (MM-021). MM-024 was an Extended Access Program (EAP) that allowed responding patients in the MM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xin, Jin, Jie, Cai, Zhen, Chen, Fangping, Zhou, Dao-bin, Yu, Li, Ke, Xiaoyan, Li, Xiao, Wu, Depei, Meng, Fanyi, DeMarco, Dena, Zhang, Jingshan, Mei, Jay, Hou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730718/
https://www.ncbi.nlm.nih.gov/pubmed/26821931
http://dx.doi.org/10.1186/s12885-016-2069-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730718/
https://www.ncbi.nlm.nih.gov/pubmed/26821931
http://dx.doi.org/10.1186/s12885-016-2069-8

Ejemplares similares